Neutralization of ARCoV-induced sera against SARS-CoV-2 variants

• Main Authors: Xiao-Feng Li (Author), Na-Na Zhang (Author), Yu-Hua Li (Author), Shou-Chun Cao (Author), Yi-Fei Zhang (Author), Cheng-Feng Qin (Author)
• Format: Book
• Published: Taylor & Francis Group, 2022-11-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

ARCoV is a candidate mRNA vaccine encoding receptor-binding domain of SARS-CoV-2. Its safety, tolerability, and immunogenicity profile have been confirmed in the phase 1 clinical trial in China. A multi-regional phase 3 clinical trial is currently underway to test the efficacy of ARCoV (NCT04847102)...